—

Bachem Holding AG (BANB.SW) — the peer cohort

As of 2026-10-15 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Bachem Holding AG ranks 7 of 7 in its cohort on the Closelooknet composite (51/100) — the cohort is led by Halozyme Therapeutics Inc at 75/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
BANB.SW Bachem Holding AG 51 85 40 32 ok 0%
HALO Halozyme Therapeutics Inc 75 98 94 47 ok 0.7%
ARGX.BR Argen-X 64 64 75 28 info 18%
ONC BeiGene, Ltd. 64 84 63 30 ok 2.9%
ARGX argenx NV ADR 62 56 74 28 info 21.1%
UCB.BR UCB SA 61 20 70 57 warn 28.5%
KRYS Krystal Biotech Inc 60 64 85 16 info 13.7%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-15

Quick answers

Who are Bachem Holding AG's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Halozyme Therapeutics Inc (HALO), Argen-X (ARGX.BR), BeiGene, Ltd. (ONC), argenx NV ADR (ARGX), UCB SA (UCB.BR), Krystal Biotech Inc (KRYS).

How does BANB.SW score against its peers?

Bachem Holding AG's composite reads 51/100, ranking 7 of 7 in its cohort as of 2026-10-15; the cohort's highest composite is Halozyme Therapeutics Inc at 75/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.